Novaerus completes the infection prevention loop with its airborne pathogen control technology, which is deployed in hundreds of skilled nursing and assisted living facilities across North America and Europe. Novaerus' unique air sterilization technology uses a patented plasma barrier to help reduce the presence of airborne bacteria, pathogens, mold, allergens and odors, and has been proven effective against even the most harmful contaminants including MRSA, C-diff, Norovirus and influenza. Providing residents and staff with a cleaner, healthier environment the Novaerus technology helps facilities realize measurable financial and clinical benefits, including the ability to lower spending associated with airborne illnesses, decrease resulting hospital readmissions rates, and protect and drive census.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
11/19/14 | $10,000,000 |
Polaris Partners | undisclosed |